| Overview |
| bsm-54677R |
| EWSR1 Recombinant Antibody |
| WB, IHC-P, IF(ICC), IHC |
| Human, Mouse, Rat |
| Specifications |
| Unconjugated |
| Rabbit |
| Synthetic Peptide within N terminal human EWSR1/EWS. |
| Monoclonal |
| #REF! |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20C for 12 months. |
| Target |
| 2130 |
| Q01844 |
| Cytoplasm, Nucleus, Plasma membrane |
| bK984G1.4 antibody, bK984G1.4 Ewing sarcoma breakpoint region 1 protein antibody, Ewing sarcoma breakpoint region 1 antibody, Ewing sarcoma breakpoint region 1 protein antibody, Ewings sarcoma EWS Fli1 type 1 oncogene antibody, EWS antibody, EWS oncogene antibody, EWS RNA binding protein 1 antibody, EWS_HUMAN antibody, EWSR 1 antibody, Ewsr1 antibody, EWSR1 protein antibody, RNA binding protein EWS antibody, RNA-binding protein EWS antibody |
| EWS is a nuclear RNA-binding protein. As a result of chromosome translocation, the EWS gene is fused to a variety of transcription factors, including ATF-1 in human neoplasias. In the Ewing family of tumors, the N-terminal domain of EWS is fused to the DNA-binding domain of various ETS transcription factors, including Fli-1, Erg, ETV1, E1AF and FEV. The EWS/Fli-1 chimeric protein acts as a more potent transcriptional activator than Fli-1 and can promote cell transformation. Two functional regions have been identified in EWS; an amino-terminal region (domain A), that has little transactivation activity but transforms efficiently when fused to Fli-1, and a distal region (domain B), which shows transactivation activity but transforms less efficiently when fused to Fli-1. |
| Application Dilution |
| WB |
1:300-5000 |
| IHC-P |
1:200-400 |
| IF(ICC) |
1:50-200 |
| IHC |
|